Skip to main content
. 2023 May 18;24(10):8945. doi: 10.3390/ijms24108945

Figure 4.

Figure 4

Imbalance between coagulation and fibrinolysis: the effects of SARS-CoV2. (a). Physiologically, ACE-2 reduces the availability of angiotensin II with no effects on coagulation and fibrinolysis. (b). SARS-CoV2 reducing ACE-2 availability, which increases the level of angiotensin II and the PAI-1 and favors the activation of the coagulation system. ACE-2: angiotensin-converting enzyme 2, PAI-1: plasminogen activator inhibitor 1.